{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:30:10Z","timestamp":1787675410093,"version":"build-2784847793"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"am","delay-in-days":271,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R01HL163168"],"award-info":[{"award-number":["R01HL163168"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.vph.2025.107475","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T08:17:12Z","timestamp":1740471432000},"page":"107475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Survivin in cardiovascular diseases and its therapeutic potential"],"prefix":"10.1016","volume":"159","author":[{"given":"Thomas","family":"Mousso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanh","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Drewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sefunmi","family":"Babatunde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Inserra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Biber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Brazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Gupte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongho","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2025.107475_bb0005","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41586-022-05060-x","article-title":"Spatial multi-omic map of human myocardial infarction","volume":"608","author":"Kuppe","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vph.2025.107475_bb0010","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.223826","article-title":"Survivin at a glance","volume":"132","author":"Wheatley","year":"2019","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.vph.2025.107475_bb0015","doi-asserted-by":"crossref","first-page":"113687","DOI":"10.18632\/oncotarget.22823","article-title":"Elucidating respective functions of two domains BIR and C-helix of human IAP survivin for precise targeted regulating mitotic cycle, apoptosis and autophagy of cancer cells","volume":"8","author":"Hu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.vph.2025.107475_bb0020","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1007\/s13277-015-3865-5","article-title":"Survivin splice variants and their diagnostic significance","volume":"36","author":"Sah","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.vph.2025.107475_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1476-4598-4-11","article-title":"Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies","volume":"4","author":"Caldas","year":"2005","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.vph.2025.107475_bb0030","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.7150\/thno.20005","article-title":"Subcellular localization of survivin determines its function in cardiomyocytes","volume":"7","author":"Tsang","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.vph.2025.107475_bb0035","doi-asserted-by":"crossref","first-page":"ra80","DOI":"10.1126\/scisignal.aab1624","article-title":"Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion","volume":"8","author":"Rivadeneira","year":"2015","journal-title":"Sci. Signal."},{"key":"10.1016\/j.vph.2025.107475_bb0040","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1007\/s13277-015-3865-5","article-title":"Survivin splice variants and their diagnostic significance","volume":"36","author":"Sah","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.vph.2025.107475_bb0045","doi-asserted-by":"crossref","first-page":"23130","DOI":"10.1074\/jbc.M300957200","article-title":"Direct interaction between survivin and Smac\/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis","volume":"278","author":"Song","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2025.107475_bb0050","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1093\/emboj\/cdg263","article-title":"HBXIP functions as a cofactor of survivin in apoptosis suppression","volume":"22","author":"Marusawa","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.vph.2025.107475_bb0055","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrm3474","article-title":"The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis","volume":"13","author":"Carmena","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.vph.2025.107475_bb0060","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00412-004-0307-3","article-title":"Chromosomal passengers: the four-dimensional regulation of mitotic events","volume":"113","author":"Vagnarelli","year":"2004","journal-title":"Chromosoma"},{"key":"10.1016\/j.vph.2025.107475_bb0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1126\/science.1189505","article-title":"Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B","volume":"330","author":"Kelly","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.vph.2025.107475_bb0070","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1091\/mbc.e11-06-0569","article-title":"Role of Survivin in cytokinesis revealed by a separation-of-function allele","volume":"22","author":"Szafer-Glusman","year":"2011","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.vph.2025.107475_bb0075","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1074\/jbc.M211119200","article-title":"Survivin enhances Aurora-B kinase activity and localizes Aurora-B in human cells","volume":"278","author":"Chen","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2025.107475_bb0080","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","article-title":"A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma","volume":"3","author":"Ambrosini","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.vph.2025.107475_bb0085","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/70487","article-title":"Analysis of human transcriptomes","volume":"23","author":"Velculescu","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.vph.2025.107475_bb0090","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7150\/jca.13332","article-title":"Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies","volume":"7","author":"Chen","year":"2016","journal-title":"J. Cancer"},{"key":"10.1016\/j.vph.2025.107475_bb0095","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/nnm-2017-0286","article-title":"Recent advances in nanomedicine and survivin targeting in brain cancers","volume":"13","author":"Mazur","year":"2018","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.vph.2025.107475_bb0100","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/jcp.29027","article-title":"The survivin molecule as a double-edged sword in cellular physiologic and pathologic conditions and its role as a potential biomarker and therapeutic target in cancer","volume":"235","author":"Rafatmanesh","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.vph.2025.107475_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101446","article-title":"Survivin is essential for thermogenic program and metabolic homeostasis in mice","volume":"58","author":"Alimujiang","year":"2022","journal-title":"Mol. Metab."},{"key":"10.1016\/j.vph.2025.107475_bb0110","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0002-9440(10)64742-6","article-title":"Control of apoptosis during angiogenesis by survivin expression in endothelial cells","volume":"156","author":"O'Connor","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.vph.2025.107475_bb0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-213X-1-5","article-title":"Developmental expression of survivin during embryonic submandibular salivary gland development","volume":"1","author":"Jaskoll","year":"2001","journal-title":"BMC Dev. Biol."},{"key":"10.1016\/j.vph.2025.107475_bb0120","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1523\/JNEUROSCI.1446-05.2005","article-title":"Essential role for survivin in early brain development","volume":"25","author":"Jiang","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.vph.2025.107475_bb0125","doi-asserted-by":"crossref","first-page":"11480","DOI":"10.1073\/pnas.0500303102","article-title":"Differential requirements for survivin in hematopoietic cell development","volume":"102","author":"Gurbuxani","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.vph.2025.107475_bb0130","first-page":"43","article-title":"Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation","volume":"152","author":"Adida","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.vph.2025.107475_bb0135","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1161\/01.ATV.0000258794.57872.3f","article-title":"IAP survivin regulates atherosclerotic macrophage survival","volume":"27","author":"Blanc-Brude","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2025.107475_bb0140","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0002-9440(10)63453-0","article-title":"Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation","volume":"163","author":"Conway","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.vph.2025.107475_bb0145","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI23203","article-title":"Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension","volume":"115","author":"McMurtry","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2025.107475_bb0150","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1161\/01.ATV.0000183885.66153.8a","article-title":"Regulation of vein graft hyperplasia by survivin, an inhibitor of apoptosis protein","volume":"25","author":"Wang","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2025.107475_bb0155","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cvr\/cvu001","article-title":"Survivin gene therapy attenuates left ventricular systolic dysfunction in doxorubicin cardiomyopathy by reducing apoptosis and fibrosis","volume":"101","author":"Lee","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.vph.2025.107475_bb0160","article-title":"Cardio-oncology: a myriad of relationships between cardiovascular disease and cancer","volume":"9","author":"Wang","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.vph.2025.107475_bb0165","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s44161-022-00028-6","article-title":"Single-cell transcriptomics reveals cell-type-specific diversification in human heart failure","volume":"1","author":"Koenig","year":"2022","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.vph.2025.107475_bb0170","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41420-021-00567-0","article-title":"Single-cell RNA-seq reveals cellular heterogeneity of mouse carotid artery under disturbed flow","volume":"7","author":"Li","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.vph.2025.107475_bb0175","doi-asserted-by":"crossref","DOI":"10.1063\/5.0157549","article-title":"Survivin regulates intracellular stiffness and extracellular matrix production in vascular smooth muscle cells","volume":"7","author":"Krajnik","year":"2023","journal-title":"APL Bioeng."},{"key":"10.1016\/j.vph.2025.107475_bb0180","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2016.12.009","article-title":"High density lipoprotein (HDL)-associated sphingosine 1-phosphate (S1P) inhibits macrophage apoptosis by stimulating STAT3 activity and survivin expression","volume":"257","author":"Feuerborn","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2025.107475_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24098062","article-title":"Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside","volume":"24","author":"Kumric","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.vph.2025.107475_bb0190","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5830\/CVJA-2011-068","article-title":"Endothelial dysfunction: the early predictor of atherosclerosis","volume":"23","author":"Mudau","year":"2012","journal-title":"Cardiovasc. J. Afr."},{"key":"10.1016\/j.vph.2025.107475_bb0195","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1042\/CS20040086","article-title":"Role of apoptosis in atherosclerosis and its therapeutic implications","volume":"107","author":"Stoneman","year":"2004","journal-title":"Clin. Sci. (Lond.)"},{"issue":"Suppl","key":"10.1016\/j.vph.2025.107475_bb0200","doi-asserted-by":"crossref","first-page":"S382","DOI":"10.1194\/jlr.R800032-JLR200","article-title":"Mechanisms and consequences of macrophage apoptosis in atherosclerosis","volume":"50","author":"Seimon","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.vph.2025.107475_bb0205","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41420-021-00567-0","article-title":"Single-cell RNA-seq reveals cellular heterogeneity of mouse carotid artery under disturbed flow","volume":"7","author":"Li","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.vph.2025.107475_bb0210","doi-asserted-by":"crossref","first-page":"1081881","DOI":"10.3389\/fphys.2022.1081881","article-title":"Vascular smooth muscle cells in intimal hyperplasia, an update","volume":"13","author":"D\u00e9glise","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.vph.2025.107475_bb0215","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jvs.2005.01.006","article-title":"Survivin expression is up-regulated in vascular injury and identifies a distinct cellular phenotype","volume":"41","author":"Simosa","year":"2005","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.vph.2025.107475_bb0220","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3109\/13880209.2014.884605","article-title":"Inhibition of neointimal hyperplasia in rats treated with atorvastatin after carotid artery injury may be mainly associated with down-regulation of survivin and Fas expression","volume":"52","author":"Xu","year":"2014","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.vph.2025.107475_bb0225","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm750","article-title":"Inhibitor of apoptosis protein survivin regulates vascular injury","volume":"8","author":"Blanc-Brude","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.vph.2025.107475_bb0230","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1097\/PCC.0b013e3181c76db3","article-title":"Emerging therapies for the treatment of pulmonary hypertension","volume":"11","author":"Stenmark","year":"2010","journal-title":"Pediatr. Crit. Care Med."},{"key":"10.1016\/j.vph.2025.107475_bb0235","doi-asserted-by":"crossref","first-page":"H1841","DOI":"10.1152\/ajpheart.00089.2011","article-title":"RNA interference-mediated survivin gene knockdown induces growth arrest and reduced migration of vascular smooth muscle cells","volume":"301","author":"Nabzdyk","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.vph.2025.107475_bb0240","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1006\/excr.1998.4359","article-title":"VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK\/ERK and SAPK\/JNK signaling","volume":"247","author":"Gupta","year":"1999","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.vph.2025.107475_bb0245","first-page":"1775","article-title":"Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms","volume":"151","author":"Karsan","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.vph.2025.107475_bb0250","doi-asserted-by":"crossref","first-page":"9102","DOI":"10.1074\/jbc.275.13.9102","article-title":"Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt\/survivin pathway","volume":"275","author":"Papapetropoulos","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2025.107475_bb0255","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00018-013-1282-8","article-title":"Vascular endothelial growth factors (VEGFs) and stroke","volume":"70","author":"Greenberg","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.vph.2025.107475_bb0260","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1073\/pnas.83.19.7297","article-title":"Basic fibroblast growth factor induces angiogenesis in vitro","volume":"83","author":"Montesano","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.vph.2025.107475_bb0265","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0002-9440(10)64964-4","article-title":"Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia","volume":"156","author":"Marti","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.vph.2025.107475_bb0270","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1111\/ejn.14169","article-title":"Survivin overexpression via adeno-associated virus vector Rh10 ameliorates ischemic damage after middle cerebral artery occlusion in rats","volume":"48","author":"Sehara","year":"2018","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.vph.2025.107475_bb0275","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00441-016-2539-y","article-title":"Pulmonary vascular remodeling in pulmonary hypertension","volume":"367","author":"Tuder","year":"2017","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.vph.2025.107475_bb0280","doi-asserted-by":"crossref","first-page":"13103","DOI":"10.1073\/pnas.240390697","article-title":"Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin","volume":"97","author":"O'Connor","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.vph.2025.107475_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1145994","article-title":"Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension","volume":"14","author":"Blanco","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.vph.2025.107475_bb0290","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/10641963.2022.2071919","article-title":"Effects of YM155 on the proliferation and apoptosis of pulmonary artery smooth muscle cells in a rat model of high pulmonary blood flow-induced pulmonary arterial hypertension","volume":"44","author":"Ye","year":"2022","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.vph.2025.107475_bb0295","first-page":"237","article-title":"The causes, consequences, and treatment of left or right heart failure","volume":"7","author":"Pazos-L\u00f3pez","year":"2011","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.vph.2025.107475_bb0300","doi-asserted-by":"crossref","first-page":"263","DOI":"10.21037\/cdt-20-302","article-title":"Pathophysiology of heart failure","volume":"11","author":"Schwinger","year":"2021","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"10.1016\/j.vph.2025.107475_bb0305","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","article-title":"Cardiac fibrosis: the fibroblast awakens","volume":"118","author":"Travers","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2025.107475_bb0310","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.15096.1","article-title":"Understanding myocardial infarction","volume":"7","author":"Saleh","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.vph.2025.107475_bb0315","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s44161-022-00028-6","article-title":"Single-cell transcriptomics reveals cell-type-specific diversification in human heart failure","volume":"1","author":"Koenig","year":"2022","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.vph.2025.107475_bb0320","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1161\/CIRCULATIONAHA.107.734160","article-title":"Survivin determines cardiac function by controlling total cardiomyocyte number","volume":"117","author":"Levkau","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2025.107475_bb0325","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00280-020-04112-1","article-title":"Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer","volume":"86","author":"Shimizu","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.vph.2025.107475_bb0330","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3109\/10428194.2015.1113275","article-title":"A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma","volume":"57","author":"Papadopoulos","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.vph.2025.107475_bb0335","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/annonc\/mdr353","article-title":"A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer","volume":"23","author":"Tolcher","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.vph.2025.107475_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249431","article-title":"Effect of sepatronium bromide (YM-155) on DNA double-strand breaks repair in cancer cells","volume":"21","author":"Majera","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.vph.2025.107475_bb0345","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1039\/D0MD00383B","article-title":"Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155)","volume":"12","author":"Wani","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.vph.2025.107475_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105474","article-title":"YM155 and BIRC5 downregulation induce genomic instability via autophagy-mediated ROS production and inhibition in DNA repair","volume":"166","author":"Cheng","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.vph.2025.107475_bb0355","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1080\/15548627.2019.1671643","article-title":"BIRC5\/Survivin is a novel ATG12-ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells","volume":"16","author":"Lin","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.vph.2025.107475_bb0360","doi-asserted-by":"crossref","DOI":"10.1063\/5.0150532","article-title":"Survivin as a mediator of stiffness-induced cell cycle progression and proliferation of vascular smooth muscle cells","volume":"7","author":"Biber","year":"2023","journal-title":"APL Bioeng."},{"key":"10.1016\/j.vph.2025.107475_bb0365","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Sign. Transduct. Target Ther."},{"key":"10.1016\/j.vph.2025.107475_bb0370","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2016.0008","article-title":"Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial","volume":"1","author":"Hammond","year":"2016","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.vph.2025.107475_bb0375","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.gt.3302802","article-title":"Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment","volume":"13","author":"Stewart","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.vph.2025.107475_bb0380","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00000658-199910000-00002","article-title":"Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA","volume":"230","author":"Rosengart","year":"1999","journal-title":"Ann. Surg."},{"key":"10.1016\/j.vph.2025.107475_bb0385","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0735-1097(03)00988-4","article-title":"A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina","volume":"42","author":"Grines","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2025.107475_bb0390","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00109-022-02208-0","article-title":"Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective","volume":"100","author":"Jt","year":"2022","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.vph.2025.107475_bb0395","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/hc1102.105595","article-title":"Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris","volume":"105","author":"Grines","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2025.107475_bb0400","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jacc.2007.06.010","article-title":"Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials","volume":"50","author":"Henry","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2025.107475_bb0405","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-4939-9065-8_9","article-title":"Current use of adenovirus vectors and their production methods","volume":"1937","author":"Sayedahmed","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.vph.2025.107475_bb0410","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1161\/01.ATV.20.6.1452","article-title":"Second-generation adenoviral vectors do not prevent rapid loss of transgene expression and vector DNA from the arterial wall","volume":"20","author":"Wen","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2025.107475_bb0415","first-page":"247","article-title":"Helper-dependent adenovirus vectors devoid of all viral genes cause less myocardial inflammation compared with first-generation adenovirus vectors","volume":"99","author":"Fleury","year":"2004","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.vph.2025.107475_bb0420","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1089\/hum.2013.071","article-title":"Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors","volume":"24","author":"Brunetti-Pierri","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.vph.2025.107475_bb0425","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1089\/hum.2010.241","article-title":"A versatile adeno-associated virus vector producer cell line method for scalable vector production of different serotypes","volume":"22","author":"Yuan","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.vph.2025.107475_bb0430","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Sign. Transd. Target. Therapy"},{"key":"10.1016\/j.vph.2025.107475_bb0435","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/s41433-024-03065-6","article-title":"Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice","volume":"38","author":"Testa","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.vph.2025.107475_bb0440","article-title":"Gene therapy for Spinal Muscular Atrophy (SMA): a review of current challenges and safety considerations for Onasemnogene Abeparvovec (Zolgensma)","volume":"15","author":"Ogbonmide","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.vph.2025.107475_bb0445","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2025.107475_bb0450","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/CIRCRESAHA.113.302421","article-title":"Long-term effects of AAV1\/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality","volume":"114","author":"Zsebo","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2025.107475_bb0455","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/HCO.0000000000000386","article-title":"Cardiac gene therapy with adeno-associated virus-based vectors","volume":"32","author":"Chamberlain","year":"2017","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.vph.2025.107475_bb0460","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2025.107475_bb0465","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeac028","article-title":"The AAV-PCSK9 murine model of atherosclerosis and metabolic dysfunction","volume":"2","author":"Keeter","year":"2022","journal-title":"Eur. Heart J. Open"},{"key":"10.1016\/j.vph.2025.107475_bb0470","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.vph.2025.107475_bb0475","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ymthe.2005.07.358","article-title":"Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice","volume":"12","author":"Themis","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.vph.2025.107475_bb0480","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMoa2400442","article-title":"Lentiviral gene therapy for cerebral adrenoleukodystrophy","volume":"391","author":"Eichler","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2025.107475_bb0485","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.vph.2025.107475_bb0490","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/eurjhf\/hfp135","article-title":"Transplantation with survivin-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction","volume":"11","author":"Fan","year":"2009","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.vph.2025.107475_bb0495","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1479-5876-9-105","article-title":"Effects of transplantation with bone marrow-derived mesenchymal stem cells modified by Survivin on experimental stroke in rats","volume":"9","author":"Liu","year":"2011","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.vph.2025.107475_bb0500","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nbt1216","article-title":"Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration","volume":"24","author":"Montini","year":"2006","journal-title":"Nat. Biotechnol."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153718912500014X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153718912500014X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:05:24Z","timestamp":1748905524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153718912500014X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":100,"alternative-id":["S153718912500014X"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2025.107475","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survivin in cardiovascular diseases and its therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2025.107475","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107475"}}